September 25th 2024
A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.
March 15th 2024
Your daily dose of the clinical news you may have missed.
March 8th 2024
Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.
January 15th 2024
Compared to the lowest intake of AS-rich food and beverages, the highest intake was associated with a 59% higher risk of developing MetS, according to new findings.
December 4th 2023
CV Risk Factors Increasing Among Middle-Aged US Adults, Socioeconomic Inequities Persist: New Findings
Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.
Social Determinants of Health Drive CVD Mortality Differences Between Black and White Adults
Excess CVD mortality among Black vs White adults was diminished after control for behavior/metabolic factors and negligible after adjustments for SDOH, a new study reveals.
Daily Dose: Vegetarian Diet Boosts Optimal Drug Therapy in High-Risk CVD Patients
A daily dose of clinical news on Patient Care you may have missed.
Vegetarian Diet May Augment Effects of Optimal Drug Therapy in Patients at High Risk of CVD
Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.
Daily Dose: The BMI vs Body Fat Debate
Your daily dose of clinical news you may have missed.
For the Statin-Intolerant or Statin-Unwilling Patient, Part 2: Other Pharmaceutical Options
For the 1 in 3 individuals with hyperlipidemia who can't or won't take a statin, preventive cardiologist Elizabeth Klodas, MD, details 3 alternative drug classes.
When Statins Are Not an Option, Part 1: Leverage Nutrition First
Preventive cardiologist Elizabeth Klodas, MD, reviews the essential elements of a plan of eating shown clinically to reduce hyperlipidemia.
The BMI vs Body Fat Debate: Study Suggests One-Third of People with Normal BMI are Obese
In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.
Choosing Between Guidelines: Statins for Primary CVD Prevention
In a recent comparison of guideline recommendations for initiating statin therapy in primary prevention, researchers found significant differences in the numbers who would benefit.
Daily Dose: Bempedoic Acid Reduces Risk for MACE in Primary Prevention Population
Bempedoic Acid Reduced Risk for MACE by 30% in Primary Prevention Population: CLEAR Outcomes Subanalysis
ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.
FDA Approves Low-Dose Colchicine as First Anti-inflammatory Therapy to Reduce Cardiovascular Events
Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.
Daily Dose: Bempedoic Acid Found Comparable to Statins for Lowering LDL-C
Bempedoic Acid Found Comparable to Statins for Lowering LDL-C, Reducing Major CV Event Risk
ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.
Friday's 5 Quotes for Primary Care - 4-7-2023
High salt intake linked to coronary atherosclerosis; daily ETOH, even in small doses, is dangerous; statins don't increase muscle injury; and 2 more studies of note.
Sodium Intake Shows Strong Linear Relationship with Risk of Both Carotid and Coronary Atherosclerosis: Population-based Study
Each 1000 mg rise in Na excretion saw a corresponding 3%, 4%, and 4% higher risk of worsening carotid plaque, CAC score, and coronary artery stenosis, respectively.
Daily Dose: Prevalence of Statin Use for ASCVD Prevention
Daily Dose: Statin-Eligible Minority Patients Sorely Undertreated
A daily dose of clinical news you may have missed.
Rate of Statin Use for Primary ASCVD Prevention Substantially Lower in Black, Hispanic Persons
Analysis of NHANES data between 2013-2020 found statin use low across racial/ethnic groups and significantly lower among Black and Hispanic participants.
Friday's 5 Quotes for Primary Care 3-10-2023
Each of the quotes is taken from a study reviewed on Patient Care during the week and was chosen for the research team’s passion about the clinical implications of their findings.
Daily Dose: Coordinated Care to Optimize CV Preventive Therapies in T2D
Residual Inflammation in Statin-treated Patients Linked to Greater Risk for MACE, Mortality vs Residual Cholesterol
Among patients in the highest quartile of hsCRP, the risks of CV-related and all-cause death were more than 2 times higher than in those in the highest quartile of LDL-C.
Likelihood of Optimal GDMT for Patients with T2D, ASCVD Increased with Multifaceted Clinic Intervention
ACC2023. For high-risk T2D patients not receiving optimal treatment for hyperlipidemia, hypertension, or hyperglycemia, intensive, multidisciplinary training for clinic staff could shift practice.
Alabama Leads Country in Medicare Prescriptions for Opioid Pain Relievers
A statin tops the list of most commonly prescribed Medicare drugs in most states. But in Alabama, it's Vicoodin, and the number of prescriptions written there exceeds the other 49 states.
Global Burden of Cardiovascular Disease, Risk Factors Detailed in New American College of Cardiology Report
Worldwide the report finds that hypertension, hypercholesterolemia, dietary risks, and air pollution are the leading causes of CVD which remains the leading cause of death globally.
Statin Treatment and Duration Associated with Reduced Risk of Hemorrhagic Stroke
Similar reduction in risk was reported for both lobar and nonlobar intracranial hemorrhage with longer statin treatment associated with greater protection, according to Danish investigators.
Bempedoic Acid Meets Primary Endpoint in Key Cardiovascular Outcomes Trial: CLEAR
Approved in 2020 as Nexletol, bempedoic acid as the first ATP citrate lyase inhibitor and oral non-statin therapy to meet the MACE-4 primary endpoint.
Statin Prescribing in Primary Care Boosted with EHR Prompts Plus Patient Alerts
An EHR prompt to a physician alone or in combination with a previsit patient prompt both increased statin prescribing in primary care but a patient prompt alone did not.
Daily Dose: ASCVD Risk Reduced by 10% with Diet
ASCVD Risk Reduced by 10% with Diet, Greater Drops Seen in Women, Black Adults
The therapeutic impact of the dietary lifestyle intervention and the differential effects could have major implications for clinical care and policy, say study authors.